| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.517 | 0.027 | 0.517 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.408 0.094 DBMET00979 | ||
| 0.458 | 0.006 | 0.458 | MAP kinase kinase 2 inhibitor | 0.448 0.007 DBMET00979 | ||
| 0.459 | 0.039 | 0.487 | GABA C receptor rho-3 antagonist | 0.487 0.03 DBMET00979 | DBMET00979 | |
| 0.414 | 0.015 | 0.426 | Cyclic AMP phosphodiesterase inhibitor | 0.426 0.013 DBMET00979 | DBMET00979 | |
| 0.32 | 0.037 | 0.35 | DNA synthesis inhibitor | 0.35 0.03 DBMET00979 | DBMET00979 | |
| 0.288 | 0.009 | 0.288 | Ferrochelatase inhibitor | 0.183 0.027 DBMET00979 | ||
| 0.292 | 0.015 | 0.292 | Histone acetyltransferase inhibitor | 0.279 0.018 DBMET00979 | ||
| 0.308 | 0.038 | 0.308 | Anticonvulsant | 0.171 0.106 DBMET00979 | ||
| 0.389 | 0.12 | 0.415 | DNA directed DNA polymerase inhibitor | 0.415 0.11 DBMET00979 | DBMET00979 | |
| 0.359 | 0.096 | 0.427 | Histamine release inhibitor | 0.427 0.062 DBMET00979 | DBMET00979 | |
| 0.296 | 0.033 | 0.303 | Growth hormone agonist | 0.303 0.032 DBMET00979 | DBMET00979 | |
| 0.264 | 0.005 | 0.264 | Phosphodiesterase V inhibitor | 0.207 0.005 DBMET00979 | ||
| 0.259 | 0.005 | 0.259 | Phosphodiesterase 5A inhibitor | 0.204 0.005 DBMET00979 | ||
| 0.263 | 0.016 | 0.263 | Antiadrenergic | 0.212 0.022 DBMET00979 | ||
| 0.261 | 0.016 | 0.261 | Adrenaline antagonist | 0.21 0.022 DBMET00979 | ||
| 0.283 | 0.041 | 0.476 | Peroxidase inhibitor | 0.476 0.012 DBMET00979 | DBMET00979 | |
| 0.352 | 0.115 | 0.352 | Beta lactamase inhibitor | 0.225 0.17 DBMET00979 | ||
| 0.271 | 0.039 | 0.297 | RNA-directed DNA polymerase inhibitor | 0.297 0.032 DBMET00979 | DBMET00979 | |
| 0.298 | 0.067 | 0.547 | Aldehyde oxidase inhibitor | 0.547 0.026 DBMET00979 | DBMET00979 | |
| 0.244 | 0.017 | 0.261 | Cell wall synthesis inhibitor | 0.261 0.014 DBMET00979 | DBMET00979 | |
| 0.245 | 0.021 | 0.245 | Alpha adrenoreceptor antagonist | 0.192 0.029 DBMET00979 | ||
| 0.27 | 0.051 | 0.27 | Psychostimulant | 0.251 0.058 DBMET00979 | ||
| 0.22 | 0.004 | 0.22 | Phosphodiesterase XI inhibitor | 0.183 0.005 DBMET00979 | ||
| 0.22 | 0.004 | 0.22 | Phosphodiesterase 11A inhibitor | 0.183 0.005 DBMET00979 | ||
| 0.214 | 0.005 | 0.246 | Heat shock protein 70 antagonist | 0.246 0.004 DBMET00979 | DBMET00979 | |
| 0.325 | 0.117 | 0.395 | Antibacterial | 0.395 0.079 DBMET00979 | DBMET00979 | |
| 0.224 | 0.018 | 0.224 | Alpha 1 adrenoreceptor antagonist | 0.168 0.026 DBMET00979 | ||
| 0.279 | 0.073 | 0.295 | Insulysin inhibitor | 0.295 0.062 DBMET00979 | DBMET00979 | |
| 0.237 | 0.035 | 0.237 | Tumour necrosis factor antagonist | 0.229 0.038 DBMET00979 | ||
| 0.259 | 0.06 | 0.321 | Tyrosine 3 hydroxylase inhibitor | 0.321 0.025 DBMET00979 | DBMET00979 | |
| 0.261 | 0.067 | 0.261 | Gastrin inhibitor | 0.206 0.14 DBMET00979 | ||
| 0.215 | 0.024 | 0.23 | MAP kinase kinase inhibitor | 0.23 0.019 DBMET00979 | DBMET00979 | |
| 0.207 | 0.017 | 0.231 | UDP-glucose 4-epimerase inhibitor | 0.231 0.015 DBMET00979 | DBMET00979 | |
| 0.286 | 0.1 | 0.344 | Cholesterol antagonist | 0.344 0.067 DBMET00979 | DBMET00979 | |
| 0.191 | 0.005 | 0.191 | MAP kinase kinase 1 inhibitor | 0.187 0.006 DBMET00979 | ||
| 0.2 | 0.016 | 0.2 | Alpha 1a adrenoreceptor antagonist | 0.137 0.026 DBMET00979 | ||
| 0.272 | 0.112 | 0.281 | Vasodilator, peripheral | 0.281 0.107 DBMET00979 | DBMET00979 | |
| 0.164 | 0.005 | 0.164 | Phosphodiesterase VI inhibitor | 0.16 0.005 DBMET00979 | ||
| 0.194 | 0.036 | 0.194 | Alpha-N-acetylglucosaminidase inhibitor | 0.171 0.044 DBMET00979 | ||
| 0.237 | 0.084 | 0.287 | Superoxide dismutase inhibitor | 0.287 0.055 DBMET00979 | DBMET00979 | |
| 0.171 | 0.021 | 0.171 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.144 0.028 DBMET00979 | ||
| 0.237 | 0.088 | 0.237 | Interleukin agonist | 0.228 0.096 DBMET00979 | ||
| 0.152 | 0.009 | 0.16 | Phosphodiesterase 6D inhibitor | 0.16 0.008 DBMET00979 | DBMET00979 | |
| 0.265 | 0.125 | 0.265 | Thioredoxin glutathione reductase inhibitor | 0.252 0.132 DBMET00979 | ||
| 0.236 | 0.096 | 0.236 | 5 Hydroxytryptamine uptake stimulant | 0.229 0.104 DBMET00979 | ||
| 0.218 | 0.078 | 0.218 | MAP kinase kinase 3 inhibitor | |||
| 0.163 | 0.028 | 0.163 | Nav1.1 sodium channel blocker | 0.154 0.031 DBMET00979 | ||
| 0.188 | 0.053 | 0.188 | Cytidine deaminase inhibitor | 0.133 0.089 DBMET00979 | ||
| 0.265 | 0.135 | 0.265 | Toll-Like receptor 7 agonist | 0.246 0.151 DBMET00979 | ||
| 0.15 | 0.02 | 0.15 | Acetylcholine M3 receptor agonist | 0.099 0.046 DBMET00979 | ||
| 0.151 | 0.022 | 0.184 | Prolactin inhibitor | 0.184 0.012 DBMET00979 | DBMET00979 | |
| 0.148 | 0.02 | 0.148 | Electrolyte absorption antagonist | 0.116 0.039 DBMET00979 | ||
| 0.174 | 0.047 | 0.174 | GABA C receptor rho-2 antagonist | 0.166 0.055 DBMET00979 | ||
| 0.149 | 0.022 | 0.149 | Alpha 1b adrenoreceptor antagonist | 0.113 0.031 DBMET00979 | ||
| 0.131 | 0.005 | 0.131 | Phospholipase D inhibitor | 0.107 0.011 DBMET00979 | ||
| 0.155 | 0.033 | 0.155 | 5 Hydroxytryptamine 3A agonist | 0.134 0.045 DBMET00979 | ||
| 0.145 | 0.026 | 0.238 | Creatine kinase inhibitor | 0.238 0.006 DBMET00979 | DBMET00979 | |
| 0.14 | 0.02 | 0.152 | NADH dehydrogenase inhibitor | 0.152 0.017 DBMET00979 | DBMET00979 | |
| 0.259 | 0.14 | 0.259 | Toll-Like receptor agonist | 0.24 0.158 DBMET00979 | ||
| 0.289 | 0.171 | 0.303 | DNA polymerase beta inhibitor | 0.303 0.164 DBMET00979 | DBMET00979 | |
| 0.127 | 0.013 | 0.127 | Biliverdin reductase inhibitor | 0.097 0.019 DBMET00979 | ||
| 0.112 | 0.005 | 0.112 | MDM2 inhibitor | 0.095 0.009 DBMET00979 | ||
| 0.124 | 0.02 | 0.124 | Bromodomain-containing protein 2 inhibitor | 0.092 0.052 DBMET00979 | ||
| 0.124 | 0.022 | 0.132 | Somatostatin 1 agonist | 0.132 0.019 DBMET00979 | DBMET00979 | |
| 0.149 | 0.047 | 0.149 | Cathepsin H inhibitor | 0.116 0.08 DBMET00979 | ||
| 0.122 | 0.021 | 0.122 | HIV-1 reverse transcriptase inhibitor | 0.106 0.028 DBMET00979 | ||
| 0.203 | 0.102 | 0.233 | Vasodilator | 0.233 0.08 DBMET00979 | DBMET00979 | |
| 0.207 | 0.107 | 0.207 | Neuropeptide Y2 antagonist | 0.203 0.114 DBMET00979 | ||
| 0.12 | 0.022 | 0.12 | Adenosine A2 receptor antagonist | 0.091 0.03 DBMET00979 | ||
| 0.183 | 0.085 | 0.202 | Anesthetic general | 0.202 0.073 DBMET00979 | DBMET00979 | |
| 0.105 | 0.009 | 0.105 | Phosphodiesterase 1A inhibitor | 0.072 0.022 DBMET00979 | ||
| 0.127 | 0.033 | 0.127 | DNA directed RNA polymerase inhibitor | 0.104 0.052 DBMET00979 | ||
| 0.152 | 0.058 | 0.152 | Sphingosine 1-phosphate receptor 5 antagonist | 0.149 0.063 DBMET00979 | ||
| 0.109 | 0.016 | 0.138 | Aldose reductase inhibitor | 0.138 0.012 DBMET00979 | DBMET00979 | |
| 0.105 | 0.014 | 0.105 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.17 | 0.08 | 0.182 | Succinate dehydrogenase inhibitor | 0.182 0.065 DBMET00979 | DBMET00979 | |
| 0.127 | 0.038 | 0.127 | Adenylate kinase inhibitor | 0.115 0.048 DBMET00979 | ||
| 0.11 | 0.021 | 0.11 | Adenosine A1 receptor antagonist | 0.092 0.025 DBMET00979 | ||
| 0.106 | 0.018 | 0.106 | Glycine receptor agonist | 0.105 0.018 DBMET00979 | ||
| 0.095 | 0.011 | 0.095 | Adenosine A2b receptor antagonist | 0.067 0.019 DBMET00979 | ||
| 0.113 | 0.032 | 0.113 | Phosphodiesterase I inhibitor | 0.104 0.04 DBMET00979 | ||
| 0.2 | 0.121 | 0.202 | 5 Hydroxytryptamine release stimulant | 0.202 0.12 DBMET00979 | DBMET00979 | |
| 0.13 | 0.051 | 0.234 | Cystathionine beta-synthase inhibitor | 0.234 0.018 DBMET00979 | DBMET00979 | |
| 0.098 | 0.021 | 0.098 | Acetylcholine M5 receptor agonist | |||
| 0.087 | 0.009 | 0.087 | Kinesin antagonist | 0.081 0.01 DBMET00979 | ||
| 0.087 | 0.009 | 0.087 | Kinesin-like protein 1 inhibitor | 0.081 0.01 DBMET00979 | ||
| 0.198 | 0.122 | 0.221 | Spasmolytic | 0.221 0.105 DBMET00979 | DBMET00979 | |
| 0.078 | 0.004 | 0.078 | Phosphodiesterase 6C inhibitor | 0.07 0.005 DBMET00979 | ||
| 0.111 | 0.038 | 0.111 | Triose-phosphate isomerase inhibitor | 0.105 0.043 DBMET00979 | ||
| 0.21 | 0.138 | 0.21 | Ca2+/calmodulin-dependent kinase IV inhibitor | |||
| 0.093 | 0.023 | 0.093 | Carbamoyl phosphate synthetase inhibitor | 0.087 0.025 DBMET00979 | ||
| 0.283 | 0.213 | 0.343 | Caspase 9 stimulant | 0.343 0.151 DBMET00979 | DBMET00979 | |
| 0.275 | 0.207 | 0.275 | MAP kinase 1 inhibitor | |||
| 0.09 | 0.026 | 0.09 | Alpha 1d adrenoreceptor antagonist | 0.06 0.041 DBMET00979 | ||
| 0.177 | 0.114 | 0.177 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.111 | 0.049 | 0.111 | GABA C receptor rho-1 antagonist | 0.1 0.062 DBMET00979 | ||
| 0.196 | 0.136 | 0.196 | 5 Hydroxytryptamine 1E antagonist | 0.183 0.151 DBMET00979 | ||
| 0.09 | 0.032 | 0.09 | Alpha adrenoreceptor agonist | 0.078 0.039 DBMET00979 | ||
| 0.095 | 0.038 | 0.135 | Porphobilinogen synthase inhibitor | 0.135 0.024 DBMET00979 | DBMET00979 | |
| 0.123 | 0.066 | 0.123 | DNA repair enzyme inhibitor | 0.121 0.07 DBMET00979 | ||
| 0.08 | 0.024 | 0.168 | Alcohol oxidase inhibitor | 0.168 0.009 DBMET00979 | DBMET00979 | |
| 0.058 | 0.003 | 0.058 | DNA polymerase III inhibitor | 0.049 0.004 DBMET00979 | ||
| 0.079 | 0.024 | 0.079 | Alpha 1 adrenoreceptor agonist | 0.063 0.033 DBMET00979 | ||
| 0.089 | 0.034 | 0.089 | Adenosine A3 receptor antagonist | 0.079 0.044 DBMET00979 | ||
| 0.1 | 0.048 | 0.109 | Thioredoxin inhibitor | 0.109 0.039 DBMET00979 | DBMET00979 | |
| 0.079 | 0.028 | 0.079 | Glutamate (mGluR7) antagonist | 0.073 0.038 DBMET00979 | ||
| 0.056 | 0.005 | 0.056 | Phosphodiesterase 6B inhibitor | 0.045 0.009 DBMET00979 | ||
| 0.058 | 0.008 | 0.058 | Calcitonin gene-related peptide antagonist | 0.025 0.017 DBMET00979 | ||
| 0.137 | 0.087 | 0.137 | Ca2+-transporting ATPase inhibitor | 0.136 0.09 DBMET00979 | ||
| 0.13 | 0.081 | 0.13 | Nav1.6 sodium channel blocker | |||
| 0.088 | 0.04 | 0.088 | Interferon agonist | 0.078 0.056 DBMET00979 | ||
| 0.064 | 0.016 | 0.064 | Phosphodiesterase 7A inhibitor | 0.053 0.033 DBMET00979 | ||
| 0.097 | 0.049 | 0.097 | Acetylcholine agonist | |||
| 0.105 | 0.059 | 0.128 | Bronchodilator | 0.128 0.04 DBMET00979 | DBMET00979 | |
| 0.098 | 0.054 | 0.139 | Alcohol dehydrogenase inhibitor | 0.139 0.024 DBMET00979 | DBMET00979 | |
| 0.123 | 0.08 | 0.123 | Phosphodiesterase inhibitor | |||
| 0.066 | 0.023 | 0.066 | Acetylcholine M2 receptor agonist | 0.049 0.044 DBMET00979 | ||
| 0.118 | 0.076 | 0.118 | Nav1.3 sodium channel blocker | |||
| 0.053 | 0.011 | 0.053 | Acetylcholine M4 receptor agonist | |||
| 0.072 | 0.032 | 0.072 | Interferon inducer | 0.063 0.047 DBMET00979 | ||
| 0.082 | 0.042 | 0.082 | Glutamate dehydrogenase inhibitor | 0.081 0.043 DBMET00979 | ||
| 0.052 | 0.013 | 0.052 | p53 inhibitor | 0.036 0.024 DBMET00979 | ||
| 0.045 | 0.006 | 0.045 | Adenosine uptake inhibitor | 0.035 0.024 DBMET00979 | ||
| 0.059 | 0.02 | 0.059 | Sodium/calcium exchanger inhibitor | 0.05 0.033 DBMET00979 | ||
| 0.073 | 0.035 | 0.073 | Adenosine A2a receptor antagonist | 0.062 0.043 DBMET00979 | ||
| 0.067 | 0.029 | 0.067 | Acetylcholine muscarinic agonist | |||
| 0.092 | 0.054 | 0.092 | Histamine N-methyltransferase inhibitor | 0.081 0.065 DBMET00979 | ||
| 0.069 | 0.031 | 0.069 | Phosphodiesterase 1B inhibitor | 0.059 0.043 DBMET00979 | ||
| 0.102 | 0.064 | 0.102 | Alpha 2c adrenoreceptor antagonist | |||
| 0.046 | 0.009 | 0.046 | Uridine phosphorylase inhibitor | 0.041 0.011 DBMET00979 | ||
| 0.053 | 0.017 | 0.053 | Thymidine kinase inhibitor | 0.043 0.025 DBMET00979 | ||
| 0.059 | 0.022 | 0.059 | Acetylcholine M1 receptor agonist | |||
| 0.068 | 0.032 | 0.068 | Corticotropin releasing factor 2 receptor antagonist | |||
| 0.04 | 0.004 | 0.04 | Acid ceramidase inhibitor | 0.026 0.016 DBMET00979 | ||
| 0.057 | 0.024 | 0.057 | Bromodomain-containing protein 3 inhibitor | |||
| 0.048 | 0.017 | 0.048 | Kainate receptor agonist | 0.046 0.02 DBMET00979 | ||
| 0.052 | 0.022 | 0.052 | Leukocyte elastase inhibitor | |||
| 0.103 | 0.073 | 0.103 | GABA C receptor antagonist | 0.1 0.078 DBMET00979 | ||
| 0.06 | 0.031 | 0.096 | NMDA 2B receptor antagonist | 0.096 0.016 DBMET00979 | DBMET00979 | |
| 0.068 | 0.038 | 0.068 | NMDA receptor glycine site agonist | |||
| 0.067 | 0.038 | 0.067 | Phosphodiesterase VII inhibitor | |||
| 0.033 | 0.005 | 0.033 | Phosphodiesterase 6H inhibitor | 0.029 0.009 DBMET00979 | ||
| 0.033 | 0.005 | 0.033 | Phosphodiesterase 6G inhibitor | 0.029 0.009 DBMET00979 | ||
| 0.073 | 0.048 | 0.073 | Calcium channel L-type blocker | |||
| 0.094 | 0.07 | 0.094 | Aminopeptidase B inhibitor | 0.093 0.07 DBMET00979 | ||
| 0.042 | 0.019 | 0.042 | Nociceptin (N/OFQ) receptor antagonist | 0.031 0.028 DBMET00979 | ||
| 0.031 | 0.009 | 0.031 | Glutamate (mGluR1) agonist | 0.026 0.015 DBMET00979 | ||
| 0.056 | 0.034 | 0.056 | Elastase inhibitor | |||
| 0.046 | 0.025 | 0.046 | Glutamate (mGluR4) antagonist | |||
| 0.024 | 0.003 | 0.024 | DNA polymerase III polC-type inhibitor | 0.02 0.004 DBMET00979 | ||
| 0.031 | 0.01 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.026 0.019 DBMET00979 | ||
| 0.056 | 0.036 | 0.056 | Acyl-CoA dehydrogenase inhibitor | |||
| 0.029 | 0.009 | 0.029 | Glutamate (mGluR1a) agonist | 0.021 0.017 DBMET00979 | ||
| 0.094 | 0.074 | 0.094 | GABA C receptor agonist | 0.09 0.079 DBMET00979 | ||
| 0.031 | 0.011 | 0.031 | Thymidine phosphorylase inhibitor | 0.027 0.016 DBMET00979 | ||
| 0.028 | 0.009 | 0.028 | Phosphodiesterase 6A inhibitor | 0.024 0.015 DBMET00979 | ||
| 0.2 | 0.182 | 0.211 | Vasodilator, coronary | 0.211 0.172 DBMET00979 | DBMET00979 | |
| 0.078 | 0.061 | 0.078 | Glycine receptor antagonist | |||
| 0.06 | 0.043 | 0.06 | TRPA1 antagonist | |||
| 0.191 | 0.175 | 0.191 | Immunomodulator | |||
| 0.039 | 0.023 | 0.039 | Delayed rectifier potassium channel blocker | |||
| 0.04 | 0.024 | 0.04 | TRPM8 blocker | |||
| 0.049 | 0.034 | 0.049 | Purinergic P2X antagonist | |||
| 0.038 | 0.023 | 0.038 | 5 Hydroxytryptamine 3B antagonist | |||
| 0.035 | 0.021 | 0.035 | Purinergic P2Y2 antagonist | 0.033 0.024 DBMET00979 | ||
| 0.039 | 0.025 | 0.039 | Oxytocin antagonist | |||
| 0.055 | 0.041 | 0.055 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.137 | 0.125 | 0.142 | ATPase inhibitor | 0.142 0.115 DBMET00979 | DBMET00979 | |
| 0.04 | 0.029 | 0.04 | Kainate receptor antagonist | |||
| 0.068 | 0.057 | 0.068 | Cathepsin G inhibitor | 0.065 0.06 DBMET00979 | ||
| 0.035 | 0.024 | 0.035 | Gonadotropin-releasing hormone receptor antagonist | |||
| 0.08 | 0.069 | 0.08 | mTOR complex 2 inhibitor | |||
| 0.034 | 0.024 | 0.034 | Fumarate hydratase inhibitor | |||
| 0.094 | 0.085 | 0.094 | 5 Hydroxytryptamine antagonist | |||
| 0.021 | 0.013 | 0.021 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.038 | 0.03 | 0.038 | AMPA 4 receptor antagonist | 0.038 0.03 DBMET00979 | ||
| 0.073 | 0.065 | 0.073 | Chymotrypsin inhibitor | |||
| 0.047 | 0.039 | 0.047 | HCV NS3/NS4A protease inhibitor | |||
| 0.028 | 0.02 | 0.028 | Poly(ADP-ribose) polymerase 2 inhibitor | |||
| 0.014 | 0.007 | 0.014 | Cyclin D2 inhibitor | |||
| 0.167 | 0.16 | 0.186 | Nitric-oxide synthase stimulant | 0.186 0.115 DBMET00979 | DBMET00979 | |
| 0.054 | 0.048 | 0.054 | Pregnane X receptor antagonist | 0.053 0.05 DBMET00979 | ||
| 0.054 | 0.048 | 0.054 | Calcium channel T-type blocker | |||
| 0.017 | 0.012 | 0.017 | Calcitonin gene-related peptide 1 receptor antagonist | |||
| 0.064 | 0.06 | 0.064 | Catalase inhibitor | |||
| 0.036 | 0.033 | 0.063 | Dopamine D5 agonist | 0.063 0.011 DBMET00979 | DBMET00979 | |
| 0.065 | 0.062 | 0.096 | Glutamate decarboxylase inhibitor | 0.096 0.032 DBMET00979 | DBMET00979 | |
| 0.053 | 0.051 | 0.069 | Androgen agonist | 0.069 0.031 DBMET00979 | DBMET00979 | |
| 0.062 | 0.06 | 0.119 | Histidine decarboxylase inhibitor | 0.119 0.026 DBMET00979 | DBMET00979 | |
| 0.057 | 0.056 | 0.057 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.05 | 0.049 | 0.05 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | |||
| 0.226 | 0.225 | 0.226 | MAP kinase kinase 6 inhibitor | |||
| 0.05 | 0.05 | 0.055 | Dihydroorotate oxidase inhibitor | 0.055 0.039 DBMET00979 | DBMET00979 | |
| 0.034 | 0.036 | 0.035 | Glucose-6-phosphate dehydrogenase inhibitor | 0.035 0.033 DBMET00979 | DBMET00979 | |
| 0.238 | 0.245 | 0.26 | 5 Hydroxytryptamine release inhibitor | 0.26 0.215 DBMET00979 | DBMET00979 | |
| 0.135 | 0.147 | 0.151 | Death-associated protein kinase 2 inhibitor | 0.151 0.105 DBMET00979 | DBMET00979 | |
| 0.078 | 0.092 | 0.093 | Protein kinase C zeta inhibitor | 0.093 0.06 DBMET00979 | DBMET00979 | |
| 0.029 | 0.045 | 0.041 | Dopamine D5 antagonist | 0.041 0.031 DBMET00979 | DBMET00979 | |
| 0.124 | 0.143 | 0.189 | Pyruvate kinase inhibitor | 0.189 0.087 DBMET00979 | DBMET00979 | |
| 0.047 | 0.071 | 0.068 | Dopamine D1 antagonist | 0.068 0.042 DBMET00979 | DBMET00979 | |
| 0.126 | 0.153 | 0.14 | Antimitotic | 0.14 0.132 DBMET00979 | DBMET00979 | |
| 0.014 | 0.046 | 0.022 | Dopamine D1 agonist | 0.022 0.018 DBMET00979 | DBMET00979 | |
| 0.152 | 0.187 | 0.199 | Peptidyltransferase inhibitor | 0.199 0.1 DBMET00979 | DBMET00979 | |
| 0.134 | 0.17 | 0.177 | Immunostimulant | 0.177 0.135 DBMET00979 | DBMET00979 | |
| 0.192 | 0.228 | 0.305 | Alpha-glucosidase inhibitor | 0.305 0.157 DBMET00979 | DBMET00979 | |
| 0.082 | 0.121 | 0.121 | DOPA decarboxylase inhibitor | 0.121 0.043 DBMET00979 | DBMET00979 | |
| 0.116 | 0.155 | 0.144 | CF transmembrane conductance regulator agonist | 0.144 0.087 DBMET00979 | DBMET00979 | |
| 0.069 | 0.116 | 0.089 | Estrogen-related receptor beta agonist | 0.089 0.042 DBMET00979 | DBMET00979 | |
| 0.108 | 0.155 | 0.131 | Adenylate cyclase stimulant | 0.131 0.098 DBMET00979 | DBMET00979 | |
| 0.21 | 0.257 | 0.349 | Calcium channel L-type activator | 0.349 0.118 DBMET00979 | DBMET00979 | |
| 0.127 | 0.177 | 0.178 | Neurotrophic factor enhancer | 0.178 0.1 DBMET00979 | DBMET00979 | |
| 0.073 | 0.134 | 0.147 | Amylase inhibitor | 0.147 0.066 DBMET00979 | DBMET00979 | |
| 0.053 | 0.119 | 0.082 | NMDA receptor antagonist | 0.082 0.063 DBMET00979 | DBMET00979 | |
| 0.122 | 0.193 | 0.156 | Catenin beta inhibitor | 0.156 0.091 DBMET00979 | DBMET00979 | |
| 0.171 | 0.246 | 0.23 | Interleukin 2 agonist | 0.23 0.143 DBMET00979 | DBMET00979 | |
| 0.049 | 0.127 | 0.084 | Adrenaline agonist | 0.084 0.052 DBMET00979 | DBMET00979 | |
| 0.142 | 0.22 | 0.236 | 12-Lipoxygenase inhibitor | 0.236 0.118 DBMET00979 | DBMET00979 | |
| 0.129 | 0.215 | 0.155 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.155 0.137 DBMET00979 | DBMET00979 | |
| 0.047 | 0.138 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.055 DBMET00979 | DBMET00979 | |
| 0.062 | 0.17 | 0.09 | Beta glucuronidase inhibitor | 0.09 0.087 DBMET00979 | DBMET00979 | |
| 0.041 | 0.156 | 0.07 | HIV-1 integrase inhibitor | 0.07 0.048 DBMET00979 | DBMET00979 | |
| 0.152 | 0.269 | 0.256 | 15-Lipoxygenase inhibitor | 0.256 0.16 DBMET00979 | DBMET00979 | |
| 0.055 | 0.182 | 0.098 | DNA polymerase I inhibitor | 0.098 0.088 DBMET00979 | DBMET00979 | |
| 0.026 | 0.162 | 0.055 | HIV-1 integrase (3'-Processing) inhibitor | 0.055 0.054 DBMET00979 | DBMET00979 | |
| 0.082 | 0.222 | 0.136 | NOS3 expression enhancer | 0.136 0.089 DBMET00979 | DBMET00979 | |
| 0.039 | 0.188 | 0.078 | Opioid antagonist | 0.078 0.073 DBMET00979 | DBMET00979 | |
| 0.087 | 0.24 | 0.113 | Papain-like protease (SARS coronavirus) inhibitor | 0.113 0.101 DBMET00979 | DBMET00979 | |
| 0.037 | 0.197 | 0.121 | M18 aspartyl aminopeptidase inhibitor | 0.121 0.07 DBMET00979 | DBMET00979 | |
| 0.064 | 0.226 | 0.143 | Angiogenesis stimulant | 0.143 0.127 DBMET00979 | DBMET00979 | |
| 0.014 | 0.236 | 0.032 | Estrogen-related receptor beta antagonist | 0.032 0.022 DBMET00979 | DBMET00979 | |
| 0.043 | 0.27 | 0.136 | Lipid peroxidase inhibitor | 0.136 0.079 DBMET00979 | DBMET00979 | |
| 0.075 | 0.483 | 0.212 | Sodium/bile acid cotransporter inhibitor | 0.212 0.172 DBMET00979 | DBMET00979 | |
| 0.023 | 0.545 | 0.122 | Estrogen antagonist | 0.122 0.051 DBMET00979 | DBMET00979 | |
| 0.014 | 0.553 | 0.11 | Estrogen receptor beta antagonist | 0.11 0.046 DBMET00979 | DBMET00979 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |